Evidence map›Paper›PMID 41994639›Full record

ArticleFrontiers in oncology2026

A case report and literature review of rare intracranial and extracranial dual-lesion diffuse large B-cell lymphoma with heterogeneous subtypes (GCB type + ABC type).

Yadong Liu, Xuejuan Duan, Jinlong Liu, Chen Chen, Shaoning Yin, Gang Cheng, Meijian Yang, Wei Han, Na Li, Xianbo Zhang and 1 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yadong LiuDepartment of Oncology, Hebei General Hospital, Shijiazhuang, China.
Xuejuan DuanDepartment of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Jinlong LiuGraduate School, Hebei North University, Zhangjiakou, China.
Chen ChenDepartment of Pathology, Hebei General Hospital, Shijiazhuang, China.
Shaoning YinDepartment of Hematology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Gang ChengDepartment of Oncology, Hebei General Hospital, Shijiazhuang, China.
Meijian YangDepartment of Oncology, Hebei General Hospital, Shijiazhuang, China.
Wei HanDepartment of Oncology, Hebei General Hospital, Shijiazhuang, China.
Na LiDepartment of Oncology, Hebei General Hospital, Shijiazhuang, China.
Xianbo ZhangDepartment of Oncology, Hebei General Hospital, Shijiazhuang, China.
Jing ZhaoDepartment of Oncology, Hebei General Hospital, Shijiazhuang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of malignant lymphoma in adults. According to the gene expression profile, it can be classified into germinal center B-cell (GCB) type and activated B-cell (ABC) type. Cases with coexistence of the two subtypes and cross-site involvement are extremely rare. Herein, we report a 65-year-old female patient who presented with blurred vision in the right eye. Imaging examinations revealed space-occupying lesions in the left thalamus, basal ganglia, deep temporal lobe and left temporal muscle. Pathological biopsy and immunohistochemistry confirmed that the intracranial lesion was ABC subtype DLBCL and the temporal muscle lesion was GCB subtype DLBCL. Fluorescence

Indexed as

activated B-cell typediffuse large B-cell lymphomadual-subtype coexistencegerminal center B-cell typeindividualized treatmenttemporal muscle metastasis

Identifiers

PMID41994639
PMCPMC13079187

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.